Compare GPK & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPK | VCEL |
|---|---|---|
| Founded | 2007 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2007 | 1996 |
| Metric | GPK | VCEL |
|---|---|---|
| Price | $8.72 | $43.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $10.95 | ★ $59.71 |
| AVG Volume (30 Days) | ★ 6.7M | 494.2K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.02% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,617,000,000.00 | $276,259,000.00 |
| Revenue This Year | $0.18 | $21.71 |
| Revenue Next Year | $1.95 | $16.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $8.15 | $28.95 |
| 52 Week High | $17.39 | $49.32 |
| Indicator | GPK | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 64.22 |
| Support Level | N/A | $38.19 |
| Resistance Level | $10.04 | $46.13 |
| Average True Range (ATR) | 0.32 | 1.40 |
| MACD | 0.10 | 0.37 |
| Stochastic Oscillator | 59.44 | 89.54 |
Graphic Packaging Holding Co is a holding company that manufactures and sells a variety of paper-based consumer packaging products through its subsidiaries. The company's reportable segments are; Americas Paperboard Packaging, and International Paperboard Packaging. The majority of the revenue is generated from its Americas Paperboard Packaging segment which includes paperboard packaging sold predominantly to consumer packaged goods (CPG) companies and cups, lids and food containers sold to foodservice companies and quick-service restaurants (QSR) serving the food, beverage, and consumer product markets in the Americas. Geographically, the company operates in Americas, Europe and Asia Pacific regions.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.